Table 1.
Characteristics of the study population at the time of the assessment (N = 223)
| Variable | Value |
|---|---|
| Demographics: | |
| Age (years), mean ± SD | 56 ± 12.9 |
| Male gender, n (%) | 129 (57.9) |
| PsA duration (years), mean ± SD | 16.9 ± 12.4 |
| Psoriasis skin disease duration (years), mean ± SD | 28.1 ± 14.5 |
| BMI, mean ± SD | 29.8 ± 6.1 |
| Smoking | |
| Current, n (%) | 29 (13) |
| Past, n (%) | 70 (31.4) |
| Clinical activity measures: | |
| Tender joints count, mean ± SD | 2.5 ± 5.3 |
| Swollen joint count, mean ± SD | 1.1 ± 3.3 |
| Clinical enthesitis, n (%) | 31 (13.9) |
| Dactylitis, n (%) | 9 (4) |
| PASI, mean ± SD | 2.6 ± 5.8 |
| Nail lesions, n (%) | 59 (26.4) |
| HLA-B*27 | 34 (15.5) |
| Radiographic evaluation: | |
| modified Steinbrocker score | |
| mean ± SD | 18.7 ± 33.6 |
| median (25th, 75th percentile) | 4 (0, 20) |
| Arthritis mutilans, n (%) | 20 (9) |
| Joint ankylosis, n (%) | 26 (11.7) |
| Periostitis, n (%) | 49 (22.2) |
| mSASSS, | |
| mean ± SD | 1.7 ± 7.2 |
| median (25th, 75th percentile) | 0 (0, 0) |
| Sacroiliitis, n (%), | 82 (37.1) |
| Sonographic evaluation: | |
| MASEI, mean ± SD | 15.7 ± 12.6 |
| Treatment: | |
| DMARDs – current use, n (%) | 102 (45.7) |
| DMARDs – ever use, n (%) | 181 (81.2) |
| Biologics – current use, n (%) | 119 (53.4) |
| Biologics – ever use, n (%) | 130 (58.3) |
PsA psoriatic arthritis, BMI body mass index, BODPASI psoriasis area and severity index, HLA-B*27 human leukocyte antigen B*27, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, MASEI MAdrid Sonography Enthesitis Index, DMARDs disease-modifying antirheumatic drugs